CagriSema is an investigational obesity and type 2 diabetes medicine from Novo Nordisk that puts two different appetite hormones to work in a single weekly shot: cagrilintide, a long-acting version of the natural hormone amylin, and semaglutide, the GLP-1 already sold as Ozempic and Wegovy. In its late-stage REDEFINE trials it drove roughly 20-23% average weight loss over 68 to 84 weeks. That is a large effect. It is also, honestly, less than the market was hoping for — and in the one head-to-head study, it did not beat the tirzepatide already on pharmacy shelves. As of July 2026, CagriSema is not approved anywhere and cannot be prescribed.
New to this class of drugs? Start with our plain-English explainer on how GLP-1 medicines work, then see the whole weight and metabolism hub. CagriSema sits alongside other pipeline drugs we track honestly, including retatrutide, mazdutide and survodutide. For what is available today, compare tirzepatide (Mounjaro and Zepbound) and semaglutide.
What CagriSema actually is
Most weight-loss injections that have reached the market work on one hormone pathway. Semaglutide and tirzepatide are incretin drugs — they mimic gut hormones (GLP-1, and for tirzepatide also GIP) that curb appetite and slow how fast the stomach empties. CagriSema takes a different route by combining two mechanisms in one fixed-dose pen:
- Cagrilintide is a long-acting amylin analog. Amylin is a hormone released alongside insulin that signals fullness and helps regulate how quickly food leaves the stomach. A weekly amylin analog is a genuinely new idea in obesity care.
- Semaglutide is the same GLP-1 receptor agonist found in Wegovy and Ozempic.
The theory is that stacking an amylin pathway on top of GLP-1 produces more appetite reduction than either alone. The pivotal trials tested a fixed combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, given once weekly under the skin. Because CagriSema is investigational, there is no approved dose, no titration schedule you can follow, and nothing to buy — the numbers below describe what researchers studied, not a regimen anyone should attempt.
Is CagriSema FDA-approved? Where it stands right now
No. As of mid-2026, CagriSema is not approved anywhere in the world and cannot be prescribed. Novo Nordisk submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration in December 2025 for adults with obesity, or overweight plus at least one weight-related health condition. The FDA is expected to review the application through 2026, with a decision anticipated later in the year. A separate diabetes program (REIMAGINE) is also underway. Until the FDA acts, CagriSema exists only inside clinical trials.
| Question | What we know |
|---|---|
| What it is | A once-weekly injection combining cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1), developed by Novo Nordisk. |
| Regulatory status | Investigational. NDA filed with the U.S. FDA in December 2025; decision expected later in 2026. Not approved or available anywhere. |
| Best trial signal | About 22.7% average weight loss over 68 weeks in adults with obesity (REDEFINE 1), published in the New England Journal of Medicine. |
| Key caveat | Results landed below the roughly 25% the market expected, and CagriSema did not beat approved tirzepatide in a direct comparison. |
What the REDEFINE trials actually show
Novo Nordisk tested CagriSema in a program of large Phase 3 studies called REDEFINE. Three read-outs matter most, and reading them honestly means holding the strong results and the disappointments side by side.
REDEFINE 1 (obesity, no diabetes). This 68-week trial enrolled 3,417 adults with obesity or overweight plus a related condition, and no type 2 diabetes. Average weight loss was 22.7% with CagriSema, versus roughly 2% with placebo. Among people who stayed on the full treatment, about 40% lost at least a quarter of their body weight. Those are impressive figures — comfortably above what semaglutide alone achieves. The newsworthy nuance: when Novo Nordisk first reported the topline in December 2024, investors had been primed to expect around 25%, and the 22.7% result sent the company's shares sharply lower on the day. The drug worked well; it simply did not clear an unusually high bar the market had set for it.
REDEFINE 2 (obesity plus type 2 diabetes). In people who also have diabetes — where weight loss from these drugs is typically smaller — CagriSema produced roughly 14-16% weight loss over 68 weeks, depending on how the data are analyzed, versus about 3% on placebo. That is consistent with the pattern seen across the whole GLP-1 class, where diabetes blunts the weight-loss response.
REDEFINE 4 (head-to-head against tirzepatide). This is the honest gut-check. In an open-label 84-week study of 809 adults, CagriSema was compared directly against tirzepatide 15 mg, the approved obesity drug sold as Zepbound. CagriSema produced about 23% weight loss versus about 25.5% for tirzepatide (assuming full adherence), and it did not meet its primary goal of showing it was "no worse than" tirzepatide. In plain terms: given the choice in a single trial, the approved drug edged out the newcomer. Novo Nordisk is continuing development, including studies of a higher dose, but this result reset expectations.
How CagriSema compares with approved options
Cross-trial comparisons are imperfect — different populations, durations and designs — so treat the table below as a rough map, not a league table. The one apples-to-apples signal we have (REDEFINE 4) favored tirzepatide.
| Drug | How it works | Average weight loss in pivotal trial | Status |
|---|---|---|---|
| CagriSema (cagrilintide + semaglutide) | Amylin analog plus GLP-1 | ~22.7% at 68 weeks (REDEFINE 1) | Investigational |
| Tirzepatide (Zepbound, Mounjaro) | GIP plus GLP-1 | ~21% at 72 weeks (SURMOUNT-1) | FDA-approved |
| Semaglutide (Wegovy) | GLP-1 | ~15% at 68 weeks (STEP 1) | FDA-approved |
The takeaway is not "CagriSema failed." It clearly outperforms semaglutide alone and lands in the same neighborhood as the most effective approved drug. The takeaway is that the leap many people expected — a decisive new best-in-class — did not materialize in the data released so far. For anyone weighing real options today, tirzepatide and semaglutide are the medicines a clinician can actually prescribe; our comparison of tirzepatide and guide to semaglutide cover those in depth, and the weight-loss projector and eligibility tool can help you frame a conversation with your own doctor.
Side effects seen in the trials
CagriSema's side-effect profile in the REDEFINE trials looked much like the rest of the GLP-1 family — dominated by the gut. In REDEFINE 1, gastrointestinal side effects occurred in about 80% of people on CagriSema versus 40% on placebo. The most common were nausea (roughly 55%), constipation (about 31%) and vomiting (about 26%). Most were mild to moderate and tended to fade over time, and only about 6% of participants stopped treatment because of side effects, compared with about 4% on placebo. As with any medicine in trials, these numbers come from a controlled study with careful dose escalation and monitoring — they are not a promise of how any individual would tolerate the drug in real life. Slower-emptying stomachs and appetite suppression also raise practical concerns this class shares, including loss of muscle along with fat, which matters more the older you are.
What this means for women in midlife
Weight that shifts and settles differently in the 40s and 50s is one of the most common reasons women look into GLP-1 medicines, and the biology is real — falling estrogen changes where the body stores fat and how it uses energy. We cover this in our guide to GLP-1s for menopause-related weight gain and the broader picture of menopause weight gain. CagriSema is not part of that toolkit yet, and it would be a mistake to wait for an investigational drug when effective, approved options exist.
One point worth getting right if contraception comes up: tirzepatide can reduce the effectiveness of oral birth control pills, and its label advises a backup method after starting and after dose changes. That warning is specific to tirzepatide — semaglutide is not known to lower pill effectiveness the same way. Because CagriSema's incretin backbone is semaglutide, not tirzepatide, that particular interaction concern would not be expected to apply — but CagriSema as a combination is still investigational, and cagrilintide has a thinner safety record, so this is exactly the kind of thing to confirm with a prescriber rather than assume. Our overview of GLP-1s and birth control explains the distinction, and side effects that show up specifically in women is a useful companion read.
When to talk to a doctor — and what to avoid
Because CagriSema cannot be prescribed, there is nothing legitimate to obtain. Treat any website, clinic or "peptide" seller offering CagriSema, or standalone cagrilintide, as a red flag: it is not an approved product, and grey-market or compounded copies of investigational drugs are unregulated, unverified and potentially unsafe. We explain how to think about this in our guides to getting GLP-1s online safely and peptides marketed for weight loss.
If you are considering treatment for obesity — which medicine defines as a chronic, relapsing condition, not a willpower problem — the productive step is a conversation with a clinician about the options that actually exist. It is worth booking a visit sooner rather than later if excess weight comes with symptoms such as chest pain or breathlessness, uncontrolled blood sugar, sleep apnea, or a family history of heart disease or type 2 diabetes, because those change the risk-benefit math. A doctor can also tell you whether an approved GLP-1 fits your health picture, and what to watch for. If CagriSema is approved later in 2026, we will update this page with its label, indication and honest place among the alternatives — no sooner, and with no hype.
